Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Apr 13:6:24332.
doi: 10.1038/srep24332.

The Cumulative Cisplatin Dose Affects the Long-Term Survival Outcomes of Patients with Nasopharyngeal Carcinoma Receiving Concurrent Chemoradiotherapy

Hao Peng  1 , Lei Chen  1 , Wen-Fei Li  1 , Rui Guo  1 , Yan-Ping Mao  1 , Yuan Zhang  1 , Fan Zhang  1 , Li-Zhi Liu  2 , Li Tian  2 , Ai-Hua Lin  3 , Ying Sun  1 , Jun Ma  1
Affiliations

The Cumulative Cisplatin Dose Affects the Long-Term Survival Outcomes of Patients with Nasopharyngeal Carcinoma Receiving Concurrent Chemoradiotherapy

Hao Peng et al. Sci Rep. .

Abstract

The prognostic value of the cumulative cisplatin dose (CCD) remains controversial for patients with nasopharyngeal carcinoma (NPC) receiving only concurrent chemoradiotherapy (CCRT). We retrospectively reviewed 549 consecutive patients with non-metastatic, histologically-proven NPC treated using intensity-modulated radiotherapy (IMRT) at Sun Yat-sen university cancer center. Patient survival between different CCD groups were compared. The cut-off value of pre-treatment plasma EBV DNA (pre-DNA) and CCD based on disease-free survival (DFS) were 1460 copies/ml (AUC, 0.691; sensitivity, 0.717; specificity, 0.635) and 240 mg/m(2) (AUC, 0.506; sensitivity, 0.526; specificity, 0.538), respectively. Of the entire cohort, 92/549 (16.8%) patients received a CCD ≥ 240 mg/m(2) and 457 (83.2%) patients, < 240 mg/m(2). For CCD ≥ 240 mg/m(2) vs. < 240 mg/m(2), the estimated 4-year DFS, overall survival (OS), locoregional-free survival (LRFFS) and distant metastasis-free survival (DMFS) rates were 89.1% vs. 81.3% (P = 0.097), 92.4% vs. 90.0% (P = 0.369), 95.6% vs. 91.2% (P = 0.156), and 91.3% vs. 88.4% (P = 0.375), respectively. For the whole cohort, multivariate analysis identified the CCD was an independent prognostic factor for DFS (HR, 0.515; 95% CI, 0.267-0.995; P = 0.048). However, CCD (≥ 240 mg/m(2)) had no prognostic value in subgroup analysis with stratification by the cut-off value of pre-DNA (P > 0.05 for all rates).

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan-Meier DFS (A), OS (B), LRRFS (C) and DMFS (D) curves for patients with NPC stratified as the cumulative cisplatin dose <240 mg/m2 and ≥240 mg/m2 group. Abbreviations: DFS = disease-free survival; OS = overall survival; LRRFS = local-regional relapse-free survival; DMFS = distant metastasis-free survival.
Figure 2
Figure 2
Kaplan-Meier DFS (A), OS (B), LRRFS (C) and DMFS (D) curves for NPC patients with pre-DNA < 1460 copies/ml stratified as the cumulative cisplatin dose <240 mg/m2 and ≥240 mg/m2 group. Abbreviations: Pre-DNA = pre-treatment EBV DNA; DFS = disease-free survival; OS = overall survival; LRRFS = local-regional relapse-free survival; DMFS = distant metastasis-free survival.
Figure 3
Figure 3
Kaplan-Meier DFS (A), OS (B), LRRFS (C) and DMFS (D) curves for NPC patients with pre-DNA ≥ 1460 copies/ml stratified as the cumulative cisplatin dose <240 mg/m2 and ≥240 mg/m2 group. Abbreviations: Pre-DNA = pre-treatment EBV DNA; DFS = disease-free survival; OS = overall survival; LRRFS = local-regional relapse-free survival; DMFS = distant metastasis-free survival.
See this image and copyright information in PMC

References

    1. Jemal A., Bray F. & Center M. M. Global cancer statistics. CA Cancer J Clin. 61, 69–90 (2011). - PubMed
    1. Lee A. W., Ng W. T. & Chan L. K. The strength/weakness of the AJCC/UICC staging system (7th edition) for nasopharyngeal cancer and suggestions for future improvement. Oral Oncol. 48, 1007–13 (2012). - PubMed
    1. Al-Sarraf M., LeBlanc M. & Giri P. G. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol. 16, 1310–7 (1998). - PubMed
    1. Chan A. T., Leung S. F. & Ngan R. K. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst. 97, 536–9 (2005). - PubMed
    1. Lee A. W., Lau W. H. & Tung S. Y. Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group. J Clin Oncol. 23, 6966–75 (2005). - PubMed

Publication types